Comparing the current results to its competitors, Intelgenx Technologies reported Revenue increase in the 1 quarter 2024 by 7.41 % year on year. The revenue growth was below Intelgenx Technologies 's competitors' average revenue growth of 10.45 %, achieved in the same quarter.
Intelgenx Technologies 's Comment on Competition and Industry Peers
The pharmaceutical industry is characterized by intense competition, rapid technological advancements, and regulatory challenges. Key competitors include Aquestive (formerly Monosol Rx), Tesa-Labtec GmbH, Collegium Pharmaceutical Inc. (formerly BioDelivery Sciences International, Inc.), and LTS Lohmann Therapy Systems Corp. These companies have longer operating histories and possess greater financial, technical, marketing, legal, and other resources. They also have more extensive experience in conducting clinical trials, securing FDA and other regulatory approvals, and marketing approved products. The company anticipates competition from numerous other firms currently operating or planning to enter the market. The company’s competitive strengths include a comprehensive service portfolio, rapid product development leading to regulatory approval, versatile drug delivery technologies, and a highly qualified professional team. The company depends on a limited number of major customers and partners for product development, funding, regulatory approvals, and marketing.
Publicly Traded Peers of Intelgenx Technologies Corp
Anebulo Pharmaceuticals Inc Share Performance
-87.20%
One Year
Anebulo Pharmaceuticals Inc
Profile
Anebulo Pharmaceuticals Inc operates on a business model focused on developing and commercializing innovative therapeutic solutions for respiratory diseases. They aim to identify and target unmet medical needs through research and development of novel drug formulations and delivery systems. By partnering with stakeholders and leveraging their expertise, Anebulo Pharmaceuticals Inc aims to provide effective treatments and improve the lives of patients with respiratory conditions.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Evoke Pharma Inc operates as a specialty pharmaceutical company focusing on the development and commercialization of drugs for the treatment of gastrointestinal disorders. Their business model involves researching, developing, and marketing innovative pharmaceutical products to address unmet medical needs in the gastrointestinal market.
Enveric Biosciences Inc's business model centers around the development and commercialization of innovative cannabinoid medicines and therapies to address various medical conditions, primarily focusing on cancer-related symptoms and improving patient outcomes. The company aims to leverage its expertise in the pharmaceutical industry to advance its pipeline, obtain regulatory approvals, and establish strategic partnerships for the distribution and sale of its products.
Sources:
Intelgenx Technologies Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Intelgenx Technologies Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
